drugset / Trial / NCT01676818
Eribulin Mesylate in Treating Patients With Advanced or Recurrent Cervical Cancer
Phase 2
Completed
32 enrolled
University of Southern California
National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
This phase II trial studies how well eribulin mesylate works in treating patients with advanced or recurrent cervical cancer. Drugs used in chemotherapy, such as eribulin mesylate, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing
Timeline
- Start
- 2012-08-09
- Primary completion
- 2021-02-21
- Completion
- 2021-12-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Eribulin | Small molecule | 1.4 mg/m2 | Intravenous |